ImmunoGen, Inc.
IMGNDelisted Feb 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000855654
ImmunoGen, Inc. was delisted on Feb 12, 2024; its insiders filed their last Form 4 on Feb 12, 2024; 327 institutions reported holding it in 13F filings for Q4 2023, worth $7.54B in total; Maverick Capital was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 327
- Q4 2023, +52 vs. previous quarter
- 13F value
- $7.54B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 1
- At the end of Q4 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2022
- $108.8M
- +55.7% year over year
- Net income, FY2022
- -$222.9M
- No comparable prior period
- Free cash flow, FY2022
- -$231.2M
- No comparable prior period
- Revenue, Q3 FY2023
- $113.4M
- +637.7% year over year
Revenue flow, FY2022
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2022: $222.9M (204.9% of revenue).
Superinvestors holding IMGN, Q4 2023
Go to the superinvestors tab1 superinvestor reports holding ImmunoGen, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by ImmunoGen, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −4.58K | $29.30 | −$134.3K | −5.9%73.3K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −12.0K | $29.30 | −$352.4K | −36.4%21.0K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Enyedy Mark JCHIEF EXECUTIVE OFFICER | SSale | −20.1K | $29.28 | −$588.7K | −3.3%584.4K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −2.63K | $29.30 | −$77.1K | −15.2%14.7K after | 10b5-1 |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −187.7K | $29.64 | −$5.56M | −98.2%3.43K after | 10b5-1 |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −6.55K | $29.74 | −$194.7K | −43.7%8.45K after | 10b5-1 |
| Dec 19, 2023 (view filing) | Dec 15 | 4 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −117.4K | $29.40 | −$3.45M | −97.7%2.81K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −3.83K | $29.20 | −$111.7K | −10.4%33.1K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Peterson KristineDirector | SSale | −20.0K | $28.90 | −$578.0K | −100.0%0 after | 10b5-1 |
| Dec 1, 2023 (view filing) | Nov 29-30 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −171.2K | $28.46 | −$4.87M | −98.4%2.81K after | 2 lots10b5-1 |
Top 10 13F holders, Q4 2023
See all 327 holdersThe largest institutional positions in ImmunoGen, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 25,466,950 | $755.1M | 0.02% | +984,795+4.0% | Added |
| Ra Capital Management, L.P. | 23,750,601 | $704.2M | 11.00% | +10,428,313+78.3% | Added |
| BlackRock Inc. | 21,824,392 | $647.1M | 0.02% | +1,550,533+7.6% | Added |
| Redmile Group, LLC | 16,423,922 | $487.0M | 17.42% | −1,079,495−6.2% | Reduced |
| Janus Henderson Group PLC | 11,043,986 | $327.5M | 0.20% | −6,640,830−37.6% | Reduced |
| State Street Corp | 8,075,671 | $239.4M | 0.01% | −1,476,181−15.5% | Reduced |
| Fairmount Funds Management LLC | 5,929,592 | $175.8M | 18.58% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 5,662,500 | $167.9M | 3.15% | +5,662,500 | New |
| Norges Bank | 5,539,334 | $164.2M | 0.03% | +3,484,245+169.5% | Added |
| Geode Capital Management, LLC | 5,382,875 | $159.6M | 0.02% | +482,900+9.9% | Added |